Fig. 7: SIRT7 O-GlcNAcylation on S136 promotes tumour progression in pancreatic cancer cells.
A PANC-1 cells were transfected with shSIRT7 and rescued by SIRT7-WT and S136A. Then, the cells were treated with or without shOGT (WT, S136A, WT+shOGT, S136A+shOGT). MTT assays were performed in the indicated cells. One representative experiment of n = 3 independent experiments is shown. B, C Colony formation assays and statistical analysis of the indicated cells. One representative experiment of n = 3 independent experiments is shown. D–F The effects of SIRT7 S136A mutation on tumour xenografts in nude mice. Four groups of PANC-1 cells were injected subcutaneously into the axillae of nude mice (n = 5 for each group). Mice were sacrificed after 4 weeks, and their tumour masses were excised and weighed. Vtumour = 0.5 × L × W2. One representative experiment of n = 3 independent experiments is shown. G Xenograft samples were subjected to Ki67 and HE staining. One representative experiment of n = 3 independent experiments is shown. H A schematic model of how SIRT7 O-GlcNAcylation exerts its function in pancreatic cancer cells. The data were shown as the means ± SD. P values were calculated by two-tailed t-tests (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; NS, no significance).
